The most used parameters to characterize this preclinical model include clinical signs and symptoms (body weight, stool consistency, and morbidity), the concentration of inflammatory biomarkers (IFN-γ, MPO, TNF-α, IL-6, and IL-10), the concentration of angiogenesis markers (VEGF-A, G-CSF, CXCL1, β-catenine, PCNA, Ki-67, caspase 3 and EGF), macroscopic evaluation of the colon (ulcers, thickness, and hyperemia) and histological evaluation of the colon. This evidence concerns the gene EGF and ulcer disease.